German Center for Infection Research   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Braunschweig Germany (2012)

Organization Overview

First Clinical Trial
2014
NCT02283099
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

German Center for Infection Research

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Communicable Diseases (Phase 1)

Coronavirus Infections (Phase 1)

Hemorrhagic Fever, Ebola (Phase 1)

Hemorrhagic Fevers, Viral (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis E (Phase 2)

Infections (Phase 1)

Lung Diseases (Phase 1)

Malaria (Phase 1)

Mycobacterium Infections (Phase 1)

Tuberculosis (Phase 1)

Tuberculosis, Pulmonary (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 18